Fig. 1.

Adjusted prediction of CDR progression with baseline CSF Aβ42, p-tau, t-tau, and amyloid (PiB)-PET SUVR levels. CSF, cerebrospinal fluid; PiB-PET, Pittsburgh compound B positron emission tomography; SUVR, standardized uptake value ratio; CDR, Clinical Dementia Rating; Aβ₄₂, 42-amino acid amyloid-beta peptide; p-tau, phospho-Tau; t-tau, total-Tau; HR, hazard ratio; CI, confidence interval. RR reflects effect size for the association with a one standard deviation higher in CSF Aβ₄₂ levels and lower in SUVR, CSF t-tau and p-tau levels. Analyses were adjusted for age at onset, sex, education, APOE4, and duration of follow up. Overall cohort includes PiB-PET-positive and negative samples.